Form 4: Mirum Pharmaceuticals CFO Acquires Shares Through Employee Stock Purchase Plan

Eric Bjerkhult, CFO of Mirum Pharmaceuticals, reports the acquisition of 470 shares of common stock through the company's Employee Stock Purchase Plan on May 10, 2024.

Summary

• Eric Bjerkhult, the Chief Financial Officer of Mirum Pharmaceuticals, acquired 470 shares of common stock on May 10, 2024.
• The acquisition was made through the company's Employee Stock Purchase Plan.
• The price per share was $21.046.
• Following the transaction, Bjerkhult directly owns 14,470 shares of Mirum Pharmaceuticals.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction, but insider buying can be interpreted as a mildly positive signal.

Positives

• The CFO's participation in the Employee Stock Purchase Plan could be seen as a positive signal, indicating confidence in the company's future.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading. They provide insights into the actions of company executives and their confidence in the company's stock.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as insider buying is often viewed favorably.

Key Dates